JP2005508157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508157A5 JP2005508157A5 JP2003525655A JP2003525655A JP2005508157A5 JP 2005508157 A5 JP2005508157 A5 JP 2005508157A5 JP 2003525655 A JP2003525655 A JP 2003525655A JP 2003525655 A JP2003525655 A JP 2003525655A JP 2005508157 A5 JP2005508157 A5 JP 2005508157A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- nos
- polynucleotide
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 55
- 108090000623 proteins and genes Proteins 0.000 claims 53
- 102000004169 proteins and genes Human genes 0.000 claims 47
- 108091033319 polynucleotide Proteins 0.000 claims 23
- 102000040430 polynucleotide Human genes 0.000 claims 23
- 239000002157 polynucleotide Substances 0.000 claims 23
- 239000000126 substance Substances 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 16
- 206010060862 Prostate cancer Diseases 0.000 claims 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 4
- 210000000987 immune system Anatomy 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000010839 reverse transcription Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31666401P | 2001-08-31 | 2001-08-31 | |
| PCT/US2002/027760 WO2003020954A2 (en) | 2001-08-31 | 2002-08-30 | 205p1b5 in treatment and detection of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007065917A Division JP2007244383A (ja) | 2001-08-31 | 2007-03-14 | 癌の処置および検出において有用な２０５ｐ１ｂ５との名称の核酸および対応するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508157A JP2005508157A (ja) | 2005-03-31 |
| JP2005508157A5 true JP2005508157A5 (enExample) | 2007-05-10 |
Family
ID=23230082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003525655A Pending JP2005508157A (ja) | 2001-08-31 | 2002-08-30 | 癌の処置および検出において有用な２０５ｐ１ｂ５との名称の核酸および対応するタンパク質 |
| JP2007065917A Pending JP2007244383A (ja) | 2001-08-31 | 2007-03-14 | 癌の処置および検出において有用な２０５ｐ１ｂ５との名称の核酸および対応するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007065917A Pending JP2007244383A (ja) | 2001-08-31 | 2007-03-14 | 癌の処置および検出において有用な２０５ｐ１ｂ５との名称の核酸および対応するタンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7700749B2 (enExample) |
| EP (1) | EP1499350A4 (enExample) |
| JP (2) | JP2005508157A (enExample) |
| AU (1) | AU2002324842C9 (enExample) |
| CA (1) | CA2458915A1 (enExample) |
| IL (2) | IL160651A0 (enExample) |
| WO (1) | WO2003020954A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2242241C1 (ru) * | 2003-12-10 | 2004-12-20 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Тетрапептид, регулирующий уровень глюкозы при сахарном диабете, фармакологическое средство на его основе и способ его применения |
| US7922769B2 (en) * | 2004-09-27 | 2011-04-12 | Depuy Products, Inc. | Modular glenoid prosthesis and associated method |
| US20070031876A1 (en) * | 2005-08-08 | 2007-02-08 | Hsueh-Kung Lin | Methods of providing gene expression profiles for metastatic cancer phenotypes utilizing differentially expressed transcripts associated with circulating tumor cells |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692438B2 (ja) | 1983-10-05 | 1994-11-16 | 三菱化成株式会社 | ペプチド |
| ATE182360T1 (de) | 1989-03-14 | 1999-08-15 | Salk Inst For Biological Studi | Neuronale nikotinacetylcholinrezeptorzusammensetzungen enthaltend die beta-4 subeinheit |
| US5369028A (en) | 1990-04-03 | 1994-11-29 | The Salk Institute Biotechnology/Industrial Associates, Inc. | DNA and mRNA encoding human neuronal nicotinic acetylcholine receptor compositions and cells transformed with same |
| US6936457B1 (en) | 1990-04-03 | 2005-08-30 | Merck & Co., Inc. | DNA ENCODING HUMAN α AND β SUBUNITS OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR, CELLS TRANSFORMED THEREWITH, AND RECOMBINANT CELL LINE EXPRESSING A HUMAN α AND β SUBUNIT OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR |
| US6440681B1 (en) * | 1990-04-03 | 2002-08-27 | Merck & Co., Inc. | Methods for identifying agonists and antagonists for human neuronal nicotinic acetylcholine receptors |
| DE69434067T2 (de) * | 1993-03-08 | 2006-03-02 | Merck & Co., Inc. | Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes |
| AU1091595A (en) | 1993-11-08 | 1995-05-29 | Salk Institute Biotechnology/Industrial Associates, Inc., The | Human neuronal nicotinic acetylcholine receptor compositions and methods employing same |
| US5708142A (en) * | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
| US6485967B1 (en) | 1995-06-07 | 2002-11-26 | Merck & Co., Inc. | Human neuronal nicotinic acetylcholine receptor α6 and β3 nucleic acid |
| US6284535B1 (en) * | 1995-09-07 | 2001-09-04 | The Trustees Of Columbia University In The City Of New York | Splice variants of the heregulin gene, nARIA and uses thereof |
| US6261791B1 (en) * | 1997-03-10 | 2001-07-17 | The Regents Of The University Of California | Method for diagnosing cancer using specific PSCA antibodies |
| US6875606B1 (en) * | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
| EP1037663A2 (en) | 1997-12-16 | 2000-09-27 | Regents Of The University Of Minnesota | Methods to treat undesirable immune responses |
| WO2001059063A2 (en) | 2000-01-31 | 2001-08-16 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001062925A2 (en) * | 2000-02-24 | 2001-08-30 | Agensys, Inc. | 103p2d6: tissue specific protein highly expressed in various cancers |
| AU2001245945A1 (en) | 2000-03-23 | 2001-10-03 | Pe Corporation (Ny) | Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2001074833A2 (en) | 2000-04-03 | 2001-10-11 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the chrnb2 gene |
| AU2001249650A1 (en) | 2000-04-03 | 2001-10-15 | Anne Chew | Haplotypes of the chrnb3 gene |
| AUPQ749100A0 (en) | 2000-05-12 | 2000-06-08 | Bionomics Limited | New epilespy gene |
| US7067626B2 (en) | 2000-07-05 | 2006-06-27 | Pharmacia & Upjohn Company | Human ion channel proteins |
| EP1305450A2 (en) | 2000-07-28 | 2003-05-02 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
| DE10042177A1 (de) | 2000-08-28 | 2002-03-14 | Bayer Ag | Acetylcholinrezeptor-Untereinheiten |
| FR2813499B1 (fr) | 2000-09-04 | 2004-11-26 | Pasteur Institut | Mammifere non-humain mutant pour l'expression de la sous- unite alpha6 du recepteur nicotinique de l'acetylcholine et utilisation pour le criblage de substances susceptibles d'interagir avec ce recepteur |
| EP1474528A4 (en) * | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS |
| CA2495389A1 (en) | 2002-08-19 | 2004-02-26 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
-
2002
- 2002-08-30 JP JP2003525655A patent/JP2005508157A/ja active Pending
- 2002-08-30 IL IL16065102A patent/IL160651A0/xx unknown
- 2002-08-30 CA CA002458915A patent/CA2458915A1/en not_active Abandoned
- 2002-08-30 US US10/415,014 patent/US7700749B2/en not_active Expired - Fee Related
- 2002-08-30 EP EP02759510A patent/EP1499350A4/en not_active Withdrawn
- 2002-08-30 AU AU2002324842A patent/AU2002324842C9/en not_active Ceased
- 2002-08-30 WO PCT/US2002/027760 patent/WO2003020954A2/en not_active Ceased
-
2004
- 2004-02-29 IL IL160651A patent/IL160651A/en not_active IP Right Cessation
-
2007
- 2007-03-14 JP JP2007065917A patent/JP2007244383A/ja active Pending
-
2009
- 2009-11-30 US US12/627,998 patent/US20100086985A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513724A5 (enExample) | ||
| JP2005505271A5 (enExample) | ||
| DK2081586T3 (en) | RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES | |
| ES2397441T5 (es) | Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea | |
| US20100203060A1 (en) | Inhibitors for growth hormone and related hormones, and methods of use thereof | |
| WO2014017491A1 (ja) | Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子 | |
| JP2003505075A5 (enExample) | ||
| JP2008194039A (ja) | 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法 | |
| EA011816B1 (ru) | Белок липокалин | |
| AU2018200078A1 (en) | Mitigating Tissue Damage and Fibrosis Via Latent Transforming Growth Factor Beta Binding Protein (LTBP4) | |
| US9453050B2 (en) | Compositions for treating glioma | |
| CA2522994A1 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
| CA2919477A1 (en) | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules | |
| JP6053255B2 (ja) | 新規癌抗原ｅＥＦ２ | |
| JP2011200233A5 (enExample) | ||
| JP2008526263A (ja) | 幹細胞因子様タンパク質をコードするポリヌクレオチド | |
| JP2010131022A (ja) | Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット | |
| JP2009511017A (ja) | 幹細胞因子様タンパク質ｓｃｆａ１及びその使用 | |
| JP2005512509A5 (enExample) | ||
| JP2005508157A5 (enExample) | ||
| US20060127397A1 (en) | RAG polypeptides, nucleic acids, and their use | |
| CA2440461A1 (en) | Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer | |
| KR101868620B1 (ko) | Fgf12를 이용한 혈관 평활근세포 증식성 질환의 진단, 예방 또는 치료용 조성물 | |
| KR101150900B1 (ko) | 퇴행성 관절염 치료 조성물 | |
| JP2007224009A (ja) | 癌の予防・治療剤 |